Loading…
BeOne Medicines AG is projected to rise to $400.25 by 2027, a +33% move from its current price of $300.01. ONC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $294.86 | $300.17 | $305.59 | +0.05% |
| May 30 | $292.84 | $300.34 | $308.02 | +0.11% |
| May 31 | $291.34 | $300.50 | $309.95 | +0.16% |
| Jun 1 | $290.11 | $300.66 | $311.60 | +0.22% |
| Jun 2 | $289.04 | $300.83 | $313.09 | +0.27% |
| Jun 3 | $288.10 | $300.99 | $314.46 | +0.33% |
| Jun 4 | $287.25 | $301.16 | $315.74 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $287.25 | $301.16 | $315.74 | +0.38% |
| Week 2 | $282.76 | $302.31 | $323.21 | +0.77% |
| Week 3 | $279.60 | $303.46 | $329.36 | +1.15% |
| Week 4 | $277.14 | $304.62 | $334.83 | +1.54% |
| Week 5 | $275.11 | $305.79 | $339.89 | +1.93% |
| Week 6 | $273.39 | $306.96 | $344.64 | +2.32% |
| Week 7 | $271.90 | $308.13 | $349.19 | +2.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BeOne Medicines AG is an oncology company that engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. It has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.
BeOne Medicines AG, symbol ONC, is a healthcare stock in the oncology space with a current price of $310.25 and a market cap of $32.19B, ranking 428.
The price outlook is broadly bullish over the longer horizon, with a progression in forecasted averages from 2026 onward and substantial upside by 2030, 2040, and 2050.
A major floor 9.4% below — a decisive break under it would weaken the trend.
The nearest floor, 3.1% below — buyers have tended to step in here.
The nearest ceiling, 8.0% above — a clean break opens room to run.
A major ceiling 23.5% above — clearing it would confirm fresh momentum.
Key ONC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ONC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $306.21 | Sell | $303.53 | Sell |
| MA 10 | $303.56 | Sell | $304.18 | Sell |
| MA 20 | $303.92 | Sell | $304.57 | Sell |
| MA 50 | $301.25 | Sell | $306.57 | Sell |
| MA 100 | $317.05 | Sell | $310.82 | Sell |
| MA 200 | $321.27 | Sell | $306.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.22 | Neutral |
| Stoch RSI (14) | 27.52 | Neutral |
| CCI (20) | -33.08 | Neutral |
| Williams %R (14) | -71.06 | Info |
| MACD (12,26,9) | -0.30 | Sell |
| ROC (12) | -3.88 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 28.94 | Neutral |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | -0.32 | Sell |
| Ultimate (7,14,28) | 52.99 | Neutral |
| Momentum (10) | -15.06 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 307.27 | Sell |
| ADX (14) | 12.13 | Neutral |
| ATR (14) | 4.81 | Info |
Technical tone is BULLISH, with RSI14 at 50 and the stock hovering around key moving averages. The SMA50 sits at $300.67, while the SMA200 is at $321.19, providing near-term guideposts around price action.
Support is identified at $290.80 and resistance at $323.87, forming a framework for the next moves. The 30-day range runs from $275.45 to $349.45, indicating recent volatility within a defined corridor. Annualized volatility stands at 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $274.73 | $300.01 | $395.71 | 0% | Neutral | |
| $326.97 | $400.25 | $512.84 | +33% | Bullish | |
| $393.11 | $489.98 | $644.22 | +63% | Bullish | |
| $409.04 | $517.57 | $694.64 | +73% | Bullish | |
| $447.15 | $573.33 | $783.10 | +91% | Bullish | |
| $460.07 | $597.01 | $828.15 | +99% | Bullish | |
| $483.68 | $634.68 | $892.78 | +112% | Bullish | |
| $587.07 | $778.40 | $1,108.98 | +159% | Bullish | |
| $647.68 | $867.25 | $1,250.19 | +189% | Bullish | |
| $685.32 | $926.29 | $1,350.04 | +209% | Bullish | |
| $1,001.71 | $1,411.90 | $2,155.85 | +371% | Bullish | |
| $1,572.55 | $2,376.78 | $3,889.05 | +692% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $274.73 | $300.01 | $351.24 | +0.00% |
| June 2026 | $264.58 | $308.64 | $367.04 | +2.88% |
| July 2026 | $268.73 | $315.30 | $378.49 | +2.16% |
| August 2026 | $265.17 | $312.52 | $377.89 | -0.88% |
| September 2026 | $266.85 | $315.67 | $383.96 | +1.01% |
| October 2026 | $273.94 | $325.16 | $397.65 | +3.01% |
| November 2026 | $272.72 | $324.68 | $398.92 | -0.15% |
| December 2026 | $268.55 | $320.63 | $395.71 | -1.25% |
Click any year to see its month-by-month ONC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ONC is projected to trade between $274.73 and $395.71, averaging $300.01 — a potential gain of 0% from today's $300.01. A consolidation phase looks the most probable path here.
BeOne Medicines AG's 2027 outlook centres on $400.25, within a $326.97 to $512.84 range. That is up +33% on the projected 2026 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2028, ONC could reach as high as $644.22, with a base case around $489.98 and support toward $393.11 — roughly +63% from $300.01. Buyers look set to stay in control over this stretch.
Expect ONC to range from $409.04 to $694.64 through 2029. The $517.57 average target implies a +73% move from current prices. That is up +6% on the projected 2028 average. Momentum favours further upside here.
The ONC price prediction for 2030 points to an average of $573.33 (low $447.15, high $783.10) — a potential gain of +91% on today's $300.01. Buyers look set to stay in control over this stretch.
In 2031, ONC is projected to trade between $460.07 and $828.15, averaging $597.01 — a potential gain of +99% from today's $300.01. That is up +4% on the projected 2030 average. Momentum favours further upside here.
BeOne Medicines AG's 2032 outlook centres on $634.68, within a $483.68 to $892.78 range. That is up +6% on the projected 2031 average. That marks a +112% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ONC could reach as high as $1,108.98, with a base case around $778.40 and support toward $587.07 — roughly +159% from $300.01. Momentum favours further upside here.
Expect ONC to range from $647.68 to $1,250.19 through 2034. The $867.25 average target implies a +189% move from current prices. That is up +11% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ONC price prediction for 2035 points to an average of $926.29 (low $685.32, high $1,350.04) — a potential gain of +209% on today's $300.01. Momentum favours further upside here.
In 2040, ONC is projected to trade between $1,001.71 and $2,155.85, averaging $1,411.90 — a potential gain of +371% from today's $300.01. That is up +52% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BeOne Medicines AG's 2050 outlook centres on $2,376.78, within a $1,572.55 to $3,889.05 range. That is up +68% on the projected 2040 average. That marks a +692% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ONC today (≈ 3.333222 ONC) could be worth
$7,922.32
+$6,922.32 (+692%) by 2050 · US Dollar
Based on the average projected ONC price of $2,376.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ONCwould be worth at today's price.
$1,000 invested in ONC on May 27, 2025 (≈ 4.196215 ONC) would be worth
$1,258.91
+$258.91 (+25.9%) today · 1.26× · US Dollar
Based on a ONC entry price of $238.31 vs. today's $300.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $308.74 | $971.72 | -2.8% |
| 1 month ago | $298.9 | $1,003.71 | +0.4% |
| 3 months ago | $322.37 | $930.64 | -6.9% |
| 6 months ago | $340.61 | $880.8 | -11.9% |
| 1 year ago | $238.31 | $1,258.91 | +25.9% |
| All time (5.0y) ago | $367.01 | $817.44 | -18.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ONC forecast.
Our base-case forecast reaches $600.00 around 2032.
Implied market cap at $600.00: $56.94B
The year-by-year forecast points to a multi-year upside, starting with a 2026 average price of $310.25 and expanding to higher levels in following years.
By 2027 the average is projected to $420.20 with a 35.4% ROI and bullish sentiment; by 2028, average $512.58 with 65.2% ROI; by 2029, average $542.98 with 75% ROI; by 2030, average $604.31 with 94.8% ROI and bullish sentiment.
Further out, 2040 shows an average of $1,510.59 with a 386.9% ROI and bullish sentiment, and 2050 shows an average of $2,564.57 with a 726.6% ROI and bullish sentiment. These figures are estimates and not guarantees, and actual results can differ.
Tap a question to reveal the answer.
Avg $604.31; Min $471.23; Max $825.62; ROI 94.8%; sentiment BULLISH.
Forecasts show BULLISH sentiment from 2027 onward with rising averages (2027 $420.20, 2028 $512.58, 2029 $542.98, 2030 $604.31). These are estimates, not guarantees.
Yes, the max forecast exceeds $1,000 in several years: 2033 max $1,183.93; 2034 max $1,325.43; 2035 max $1,437.25.
Avg $1,510.59; Min $1,071.61; Max $2,306.81; ROI 386.9%; sentiment BULLISH.
BeOne Medicines AG Community Discussion
0Share your BeOne Medicines AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.